Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Hydromethylthionine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.40 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.40 |
| ▸ | SNCA | P37840 | 8/20 | 0.48 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | NOX1 | Q9Y5S8 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydromethylthionine SCHEMBL12470963 | 1.00 | SNCA (0.48) | SNCAMAPTNOX1GAAMEN1 | |
| Hydromethylthionine SCHEMBL31159642 | 1.00 | SNCA (0.48) | SNCAMAPTNOX1GAAMEN1 | |
| Hydromethylthionine SCHEMBL12592446 | 0.98 | SNCA (0.50) | SNCAMAPTNOX1GAAMEN1 | |
| Hydromethylthionine SCHEMBL29356148 | 0.98 | SNCA (0.50) | SNCAMAPTNOX1GAAMEN1 | |
| Hydromethylthionine SCHEMBL109756 | 0.98 | SNCA (0.50) | SNCAMAPTNOX1GAAMEN1 | |
| Hydromethylthionine SCHEMBL1577040 | 0.96 | SNCA (0.48) | SNCAMAPTNOX1GAAMEN1 | |
| Hydromethylthionine SCHEMBL31159644 | 0.96 | SNCA (0.48) | SNCAMAPTNOX1GAAMEN1 | |
| Hydromethylthionine SCHEMBL23683393 | 0.96 | SNCA (0.48) | SNCAMAPTNOX1GAAMEN1 | |
| Hydromethylthionine SCHEMBL25194477 | 0.96 | SNCA (0.48) | SNCAMAPTNOX1GAAMEN1 | |
| Hydromethylthionine SCHEMBL31159649 | 0.96 | SNCA (0.48) | SNCAMAPTNOX1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4385512-B1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | TAURX THERAPEUTICS MAN LTD (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4364801-B1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | TAURX THERAPEUTICS MAN LTD (GB) | 2025-11-12 | — | — | EP | disclosed |
| EP-4335517-B1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LAB LTD (SG) | 2025-08-27 | — | — | EP | disclosed |
| EP-3826639-B1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | WISTA LAB LTD (SG) | 2024-08-21 | — | — | EP | disclosed |
| EP-4385512-A1 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | WisTa Laboratories Ltd. (SG) | 2024-06-19 | — | — | EP | disclosed |
| EP-4364801-A2 | OPTIMISED DOSAGE OF DIAMINOPHENOTHIAZINES IN POPULATIONS | WisTa Laboratories Ltd. (SG) | 2024-05-08 | — | — | EP | disclosed |
| EP-4335517-A2 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WisTa Laboratories Ltd. (SG) | 2024-03-13 | — | — | EP | disclosed |
| EP-4223297-A2 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WisTa Laboratories Ltd. (SG) | 2023-08-09 | — | — | EP | disclosed |
| US-20230165877-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LABORATORIES LTD. (SG) | 2023-06-01 | — | — | US | disclosed |
| EP-3487505-B1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | WISTA LAB LTD (SG) | 2023-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165877-A1 | ADMINISTRATION AND DOSAGE OF DIAMINOPHENOTHIAZINES | ACHE, BCHE, PNMT | ACHE 1/4885SLC6A2 64/4885SLC6A3 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.